Analysis
J&J's Halda Acquisition Hits Key Prostate Drug Trial
J&J's $3.05B Halda buyout shows promise as new prostate drug clears a significant trial, impacting oncology valuations.
Stock Market Nation desk
Food, healthcare, biotechnology, wellness, and consumer health markets.
22 storiesAnalysis
J&J's $3.05B Halda buyout shows promise as new prostate drug clears a significant trial, impacting oncology valuations.